Celcuity Inc. (CELC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Celcuity Inc. (CELC) closed at USD 60.30 on 2026-10-15, a change of -18.5 % over the past year, with a market capitalization of USD 2.77B.

Celcuity Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Celcuity Inc. key figures

Previous close

USD 60.30 (2026-10-15)

1-year change

-18.5 %

Market cap

USD 2.77B

Enterprise value

USD 2.77B

P/E ratio (trailing)

-13.13

P/E ratio (forward)

-707.25

EPS (trailing)

-4.31

EPS (forward)

-0.08

PEG ratio

n/a

Price to book

-216.78

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.35

Employees

155

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Celcuity Inc.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Celcuity Inc. and compare it with other stocks.